---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-009739"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:40:52.009193+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aclaris ATI-2138 Phase 2a AD trial meets primary and key secondary endpoints; 60.5% mean EASI improvement at week 12

## Summary
- 14 patients enrolled; 10 per protocol; no SAEs or discontinuations; well tolerated with mild, transient TRAEs.
- Mean EASI improvement 60.5% (77.1% excluding one outlier); 62.5% achieved ≥4-point itch reduction at week 12.
- PD data show near-complete ITK target occupancy and downregulation of Th2, Th1/Th17, and fibrosis markers.
- Company plans to further develop ATI-2138 in alopecia areata and explore other indications.
- Preclinical work ongoing for next-gen ITK inhibitors; new INDs expected starting 2026.

## SEC filing metadata
- accession: 0001558370-25-009739
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837025009739/0001558370-25-009739-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837025009739/acrs-20250729x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-009739
- JSON: https://secwatch.observer/filing/0001558370-25-009739.json
- Plain text: https://secwatch.observer/filing/0001558370-25-009739.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.